-
Amgen Inc. et al v. Sanofi et al DC CAFC
- 1:14-cv-01317
- D. Del.
- Filed: 10/17/2014
- Closed: 10/03/2019
- Latest Docket Entry: 02/27/2023
- Judge: Richard G. Andrews
- PACER
3
Plaintiffs
4
Defendants
1
Accused
Product
7
Patents-in-Suit
1,813
Days in
Litigation
-
Amgen Inc. et al v. Sanofi et al DC CAFC
- 1:14-cv-01317
- D. Del.
- Filed: 10/17/2014
- Closed: 10/03/2019
- Latest Docket Entry: 02/27/2023
- Judge: Richard G. Andrews
- PACER
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Validity & Enforceability
| Claim | Outcome |
|---|---|
| All challenged claims |
Invalid and Valid
Entry 1061 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 7 |
The isolated monoclonal antibody of claim 2, wherein the epitope is a functional epitope.
|
Invalid (112)
Entry 302 |
| All Claims |
NA
|
Valid
Entry 1061 |
| Claim # | Claim Text | Outcome |
|---|---|---|
| 2 |
The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least S153.
|
Invalid (112)
Entry 302 |
| 7 |
The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least D238.
|
Invalid (112)
Entry 302 Entry 818 |
| 9 |
The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least I369.
|
Invalid (112)
Entry 302 |
| 15 |
The isolated monoclonal antibody of claim 1, wherein the monoclonal antibody binds to at least V380.
|
Invalid (112)
Entry 302 Entry 818 |
| 19 |
The isolated monoclonal antibody of claim 1 wherein the isolated monoclonal antibody binds to at least two of the following residues S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of PCSK9 listed in SEQ ID
view more
|
Invalid (112)
Entry 302 |
| 29 |
A pharmaceutical composition comprising an isolated monoclonal antibody, wherein the isolated monoclonal antibody binds to at least two of the following residues S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or
view more
|
Invalid (112)
Entry 302 |
| All Claims |
NA
|
Valid
Entry 1061 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Invalid and Valid
Entry 1061 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Invalid and Valid
Entry 1061 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Invalid and Valid
Entry 1061 |
| Claim | Outcome |
|---|---|
| All challenged claims |
Invalid and Valid
Entry 1061 |
-
Infringement
Aventisub LLC
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| AlirocumabPRALUENT® | US 8,829,165 B2 |
2, 7, 9, 15, 19, 29
|
Infringement
Entry 235
|
| AlirocumabPRALUENT® | US 8,859,741 B2 |
7
|
Infringement
Entry 235
|
| AlirocumabPRALUENT® | US 8,871,914 B2 |
24
|
Infringement
Entry 235
|
Regeneron Pharmaceuticals, Inc
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| AlirocumabPRALUENT® | US 8,829,165 B2 |
2, 7, 9, 15, 19, 29
|
Infringement
Entry 235
|
| AlirocumabPRALUENT® | US 8,859,741 B2 |
7
|
Infringement
Entry 235
|
| AlirocumabPRALUENT® | US 8,871,914 B2 |
24
|
Infringement
Entry 235
|
Sanofi-Aventis US
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| AlirocumabPRALUENT® | US 8,829,165 B2 |
2, 7, 9, 15, 19, 29
|
Infringement
Entry 235
|
| AlirocumabPRALUENT® | US 8,859,741 B2 |
7
|
Infringement
Entry 235
|
| AlirocumabPRALUENT® | US 8,871,914 B2 |
24
|
Infringement
Entry 235
|
Sanofi S.A.
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| AlirocumabPRALUENT® | US 8,829,165 B2 |
2, 7, 9, 15, 19, 29
|
Infringement
Entry 235
|
| AlirocumabPRALUENT® | US 8,859,741 B2 |
7
|
Infringement
Entry 235
|
| AlirocumabPRALUENT® | US 8,871,914 B2 |
24
|
Infringement
Entry 235
|